title: Convergent discriminitive, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with analogous scales from the EORTC QLQ-C30 and a trial-specific module. European Organisation for Research and Treatment of Cancer. Core Quality of Life Questionnaire.
abstract: The Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) is a measure of health-related quality of life (HRQL) that was designed to be an outcome measure for clinical trials in advanced hormone-resistant prostate cancer. The cross-sectional validity of the PROSQOLI was assessed using baseline data from a randomized trial in which HRQL was also assessed with the European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and a trial-specific quality of life module (QLM-P14). Convergent validity was assessed with the multitrait-multimethod matrix approach; discriminative validity was assessed according to conventional clinical criteria; and predictive validity was assessed by the ability to predict survival duration. These assessments provided strong support for the validity of all PROSQOLI scales except those for family/marriage relationships and passing urine; modifications of these two scales are under evaluation. The strength, consistency, and independence of the prognostic information provided by the HRQL scales were striking. Differences between the instruments were generally subtle. These data support validity of the PROSQOLI and the analogous scales from the QLQ-C30 and QLM-P14 in symptomatic men with advanced hormone resistant prostate cancer. The PROSQOLI is a short, simple, and valid measure of HRQL in this setting.
authors.affiliation: Princess Margaret Hospital, Toronto, Ontario, Canada.
authors.forename: M R
authors.initials: MR
authors.lastname: Stockler
authors.forename: D
authors.initials: D
authors.lastname: Osoba
authors.forename: P
authors.initials: P
authors.lastname: Corey
authors.forename: P J
authors.initials: PJ
authors.lastname: Goodwin
authors.forename: I F
authors.initials: IF
authors.lastname: Tannock
mesh_terms: D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D003430:Cross-Sectional Studies; D016002:Discriminant Analysis; D006801:Humans; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use*; D010147:Pain Measurement; D011241:Prednisone / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000523:psychology; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D018434:Sickness Impact Profile; D011795:Surveys and Questionnaires
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D008942:Mitoxantrone; D011241:Prednisone